NCT02069886View on ClinicalTrials.gov

Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2014

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Thalassemia (Transfusion Delendent)
Interventions
DRUG

deferasirox

125, 250, 500 mg dispersable tablets

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY